A detailed history of Tekla Capital Management LLC transactions in Seagen Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 112,331 shares of SGEN stock, worth $0. This represents 0.86% of its overall portfolio holdings.

Number of Shares
112,331
Previous 224,663 50.0%
Holding current value
$0
Previous $45.5 Million 52.47%
% of portfolio
0.86%
Previous 1.75%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

SELL
$187.64 - $206.25 $21.1 Million - $23.2 Million
-112,332 Reduced 50.0%
112,331 $21.6 Million
Q1 2023

May 10, 2023

BUY
$127.59 - $203.08 $14.3 Million - $22.8 Million
112,449 Added 100.21%
224,663 $45.5 Million
Q4 2022

Feb 10, 2023

BUY
$117.37 - $139.17 $6.9 Million - $8.19 Million
58,827 Added 110.19%
112,214 $14.4 Million
Q3 2022

Nov 01, 2022

SELL
$135.27 - $180.11 $19.2 Million - $25.5 Million
-141,796 Reduced 72.65%
53,387 $7.31 Million
Q2 2022

Jul 29, 2022

SELL
$108.81 - $179.33 $14.7 Million - $24.3 Million
-135,378 Reduced 40.95%
195,183 $34.5 Million
Q1 2022

May 13, 2022

SELL
$119.61 - $157.85 $8.25 Million - $10.9 Million
-68,966 Reduced 17.26%
330,561 $47.6 Million
Q4 2021

Feb 14, 2022

BUY
$142.57 - $190.86 $27.4 Million - $36.7 Million
192,193 Added 92.7%
399,527 $61.8 Million
Q3 2021

Nov 12, 2021

SELL
$142.45 - $169.82 $487,891 - $581,633
-3,425 Reduced 1.63%
207,334 $35.2 Million
Q2 2021

Aug 13, 2021

SELL
$135.08 - $161.1 $1.99 Million - $2.37 Million
-14,731 Reduced 6.53%
210,759 $33.3 Million
Q1 2021

May 14, 2021

SELL
$137.51 - $190.8 $9.37 Million - $13 Million
-68,129 Reduced 23.2%
225,490 $31.3 Million
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $48.3 Million - $62.2 Million
293,619 New
293,619 $51.4 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.